First-in-human single ascending-dose study of TU7710, a factor VIIa-transferrin fusion protein, v placebo in warfarin-pretreated healthy men (40 of 41 analysed): FVIIa activity rose immediately, PT/INR normalised in all treated, and all doses were well tolerated.
RCTn = 41
Kim et al. A first-in-human study assessing the safety, pharmacokinetics, and pharmacodynamics of TU7710, a recombinant factor VIIa-transferrin fusion protein, in warfarin-pretreated healthy male participants